Additionally, the combination between AMPK activators and chemotherapeutics demonstrates good results on tumour growth inhibition and prolongs remission of breast, pancreatic, prostate, lung and ovarian cancers [6,7,8,9,10]. Here, PRKAA1 is linked to neoplasm.